Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 134, Issue 3, Pages 326-329Publisher
WILEY
DOI: 10.1111/j.1365-2141.2006.06181.x
Keywords
haematopoietic progenitors; chemokines; experimental therapies; murine models
Categories
Funding
- Wellcome Trust Funding Source: Medline
Ask authors/readers for more resources
The CXCR4 antagonist, AMD3100, stimulates a rapid increase in circulating numbers of haematopoeitic progenitor cells (HPCs) in both mice and human healthy volunteers. An in situ perfusion system of the mouse femoral bone marrow was used to provide the first direct evidence that AMD3100 mobilises HPCs from the bone marrow. Structural analogues of AMD3100 demonstrated that the ability of these compounds to mobilise HPCs in vivo correlated with their capacity to antagonise CXCR4 in vitro. This model system was also used to demonstrate additive effects of AMD3100 administered acutely, with granulocyte colony-stimulating factor administered chronically, with respect to HPC mobilisation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available